Data Sheet (Cat.No.T6072)



BGT226 maleate

Chemical Properties

CAS No.: 1245537-68-1

Formula: C28H25F3N6O2·C4H4O4

Molecular Weight: 650.6

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	BGT226 maleate (NVP-BGT226) is a class I PI3K/mTOR inhibitor for PI3K $\alpha/\beta/\gamma$ (IC50: 4/63/38 nM) .
Targets(IC50)	Apoptosis, Autophagy, mTOR, PI3K
In vitro	The anti-proliferative and pro-apoptotic effects of NVP-BGT226 are independent of bcrabl status. The activation of the AKT/mTOR signal cascade is suppressed by NVP-BGT226 in a concentration- and time-dependent manner. Flow cytometric analysis exhibits an accumulation of cells in the G(0)-G(1) phase with concomitant loss in the S-phase. NVP-BGT226 displays potent growth-inhibitory activity against all tested cell lines including SCC4, TU183 and KB cell lines with the IC50 ranging from 7.4 to 30.1 nM. Notably, both Detroit 562 and HONE-1 cells, which express PIK3CA mutation H1047R, are still sensitive to the growth-inhibitory effect of NVP-BGT226 treatment. In addition, the sensitivity to NVP-BGT226 between HONE-1 cells and its cisplatin-resistant variant is almost identical. Results of the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and the analysis of caspase 3/7 and PARP indicates that NVP-BGT226 induces cancer cell death through an apoptosis-independent pathway. NVP-BGT226 induces autophagy as indicated by the aggregation and upregulation of the microtubule-associated protein light chain 3B-II, and p62 degradation. Gene silencing of Beclin1 or cotreatment of the autophagosome inhibitor, 3-methyladenine, inhibits the NVP-BGT226-induced autophagy and leads to the retrieval of colony survival.[2] NVP-BGT226 inhibits growth in common myeloma cell lines and primary myeloma cells (such as NCI-H929, U266, RPMI-8226 and OPM2 MM cell lines) at nanomolar concentrations in a time-dependent and dose-dependent manner. NVP-BGT226 inhibits phosphorylation of protein kinase B (Akt), P70S6k and 4E-BP-1 in a time-dependent and dose-dependent manner.
In vivo	In a xenografted animal model, NVP-BGT226 significantly delays tumor growth in a dose-dependent manner, along with suppressed cytoplasmic expression of p-p70 S6 kinase and the presence of autophagosome formation. NVP-BGT226 inhibits tumor growth in a dose-dependent manner in a FaDu cell xenografted mouse model. Oral administration of NVP-BGT226 at 2.5 and 5 mg/kg for 3 weeks causes 34.7% and 76.1% reduction of the tumor growth on day 21, respectively (compared with control). NVP-BGT226 displays comparable inhibition against tumor growth to rapamycin. The final volume of both groups is significantly smaller than those treated with LY294002 (a PI3K inhibitor) or the control. [2]

Page 1 of 2 www.targetmol.com

Cell Research

NCI-H929, U266, RPMI-8226 and OPM2 MM cells are seeded in 96-well plates at a concentration of 1.5×104 cells/well in RPMI medium supplemented with 10% fetal bovine serum with or without NVP-BGT226 that is to be tested. After 36 hours, BrdU-labelling solution is added (final concentration: $10 \, \mu M$), and cells are cultured for another 12 hours in a humidified atmosphere ($37 \, ^{\circ} \text{C}/5\%$ CO2). Then, the plates are centrifuged ($10 \, \text{min}$, $300 \, \text{g}$), and the supernatants are discarded. The plates are dried at $60 \, ^{\circ} \text{C}$ for 2 hours. After fixation with ethanol/HCl for 30 min at $-20 \, ^{\circ} \text{C}$, the DNA is partially digested by nuclease treatment for $30 \, \text{min}$ at $37 \, ^{\circ} \text{C}$. The cells are washed three times with medium and incubated with anti-BrdU-POD labelling solution for $30 \, \text{min}$ at $37 \, ^{\circ} \text{C}$. The anti-POD solution is removed and the cells are washed three times with washing buffer. The ABTS substrate solution is added, and absorbance is measured in a microplate reader at $405 \, \text{nm}$ with a reference wave length of $490 \, \text{nm}$.(Only for Reference)

Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble or slightly soluble),	
	DMSO: 60 mg/mL (92.22 mM), Sonication is recommended.	
	H2O: < 1 mg/mL (insoluble or slightly soluble),	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

Preparing Stock Solutions

	1mg	5mg	10mg	
1 mM	1.537 mL	7.6852 mL	15.3704 mL	
5 mM	0.3074 mL	1.537 mL	3.0741 mL	
10 mM	0.1537 mL	0.7685 mL	1.537 mL	
50 mM	0.0307 mL	0.1537 mL	0.3074 mL	

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Markman B, et al. Ann Oncol, 2012, 23(9), 2399-2408. Chang KY, et al. Clin Cancer Res, 2011, 17(22), 7116-7126. Baumann P, et al. Anticancer Drugs, 2012, 23(1), 131-138. Glienke W, et al. Tumour Biol, 2012, 33(3), 757-765.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com